Study on the Safety, Drug Levels, and Effectiveness of CC-92480 with Other Treatments for Relapsed or Refractory Multiple Myeloma

Inclusion Criteria

• Have multiple myeloma that has returned or not responded to previous treatments.
• Show signs of disease progression during or after the last treatment.
• Be unable to benefit from existing treatments due to resistance, intolerance, or ineligibility.
• Have measurable disease that can be tracked.
• Be in good general health, with a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Agree to follow a specific plan to prevent pregnancy during the study.

Exclusion Criteria

• Have active or past involvement of multiple myeloma in the central nervous system.
• Have certain other blood disorders, such as plasma cell leukemia or Waldenstrom's macroglobulinemia.
• Have significant heart problems or diseases affecting the heart.
• Have had a COVID-19 infection recently, with specific timeframes for mild or severe cases.
• Have received certain treatments before, such as CC-92480 or other specified drugs, depending on the study part.
• Have had a stem-cell transplant recently or at any time for certain types.
• Have undergone certain procedures or treatments within 14 days before starting the study, such as major surgery or radiation therapy.
• Have used any investigational drugs recently, within 28 days or a specific time based on the drug's half-life.
• Have received a COVID-19 vaccine within 14 days before starting the study.
• Other specific criteria as defined by the study protocol.